Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.

导出 LinkOut

翻译打印收藏纠错

第一作者： Blisse,Vakkalagadda

第一单位： Bristol-Myers Squibb Princeton New Jersey.

作者： Blisse,Vakkalagadda ^[1] ; Marion L,Vetter ^[1] ; Jignasa,Rana ^[1] ; Charles H,Smith ^[2] ; Jian,Huang ^[2] ; Jennifer,Karkas ^[1] ; David W,Boulton ^[3] ; Frank,LaCreta ^[1]

作者单位： Bristol-Myers Squibb Princeton New Jersey. ^[1] PPD Wilmington North Carolina. ^[2] AstraZeneca Gaithersburg Maryland. ^[3]

关键词 Bioequivalence dapagliflozin dipeptidyl peptidase‐4 inhibitor fixed‐dose combination saxagliptin sodium‐glucose cotransporter 2 inhibitor

DOI 10.1002/prp2.201

PMID 27022473

发布时间 2024-03-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览15

Pharmacology research & perspectives

2015年3卷6期

e00201页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.

Pharmacology research & perspectives

相似文献

Pharmacology research & perspectives

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.

Pharmacology research & perspectives

相似文献

Pharmacology research & perspectives

相关期刊

检索历史清除